Hostname: page-component-cd9895bd7-gvvz8 Total loading time: 0 Render date: 2024-12-18T11:45:58.806Z Has data issue: false hasContentIssue false

Clinical

Published online by Cambridge University Press:  15 June 2005

A. Goldhirsch
Affiliation:
Department of Oncology, Ospedale Civico, 6903 Lugano, Switzerland
G. Curigliano
Affiliation:
Department of Oncology, Ospedale Civico, 6903 Lugano, Switzerland

Abstract

Type
Journals Watch
Copyright
2005 Cambridge University Press

Articles in this list have been selected from material published since 2005. They represent recommended reading only.

When available the citations are linked to the abstract held on PubMed (Medline) and CrossRef.

References

Baselga J, Carbonell X, Castaneda-Soto NJ, Clemens M, Green M, Harvey V, Morales S, Barton C, Ghahramani P. Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule [Abstract]. J Clin Oncol April 2005; 23 (10): 21622171.CrossRefGoogle Scholar
Colleoni M, Rotmensz N, Peruzzotti G, Maisonneuve P, Mazzarol G, Pruneri G, Luini A, Intra M, Veronesi P, Galimberti V, Torrisi R, Cardillo A, Goldhirsch A, Viale G. Size of breast cancer metastases in axillary lymph nodes: clinical relevance of minimal lymph node involvement [Abstract]. J Clin Oncol March 2005; 23 (7): 13791389.CrossRefGoogle Scholar
Giordano SH, Kuo YF, Freeman JL, Buchholz TA, Hortobagyi GN, Goodwin JS. Risk of cardiac death after adjuvant radiotherapy for breast cancer [Abstract]. J Natl Cancer Inst March 2005; 97 (6): 419424.CrossRefGoogle Scholar
Tworoger SS, Missmer SA, Barbieri RL, Willett WC, Colditz GA, Hankinson SE. Plasma sex hormone concentrations and subsequent risk of breast cancer among women using postmenopausal hormones [Abstract]. J Natl Cancer Inst April 2005; 97 (8): 595602.CrossRefGoogle Scholar
Arriagada R, Le MG, Spielmann M, Mauriac L, Bonneterre J, Namer M, Delozier T, Hill C, Tursz T. Randomized trial of adjuvant ovarian suppression in 926 premenopausal patients with early breast cancer treated with adjuvant chemotherapy [Abstract]. Ann Oncol March 2005; 16 (3): 389396.CrossRefGoogle Scholar
Muss HB, Woolf S, Berry D, Cirrincione C, Weiss RB, Budman D, Wood WC, Henderson IC, Hudis C, Winer E, Cohen H, Wheeler J, Norton L. Cancer and Leukemia Group B. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer [Abstract]. JAMA March 2005; 293 (9): 10731081.CrossRefGoogle Scholar
Bradbury BD, Lash TL, Kaye JA, Jick SS. Tamoxifen-treated breast carcinoma patients and the risk of acute myocardial infarction and newly-diagnosed angina [Abstract]. Cancer March 2005; 103 (6): 11141121.CrossRefGoogle Scholar
Chagpar A, Middleton LP, Sahin AA, Meric-Bernstam F, Kuerer HM, Feig BW, Ross MI, Ames FC, Singletary SE, Buchholz TA, Valero V, Hunt KK. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry [Abstract]. Cancer April 2005; 103 (8): 15811586.CrossRefGoogle Scholar
Bonneterre J, Roche H, Kerbrat P, Bremond A, Fumoleau P, Namer M, Goudier MJ, Schraub S, Fargeot P, Chapelle-Marcillac I. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial [Abstract]. J Clin Oncol April 2005; 23 (12): 26862693.CrossRefGoogle Scholar
Taghian AG, Abi-Raad R, Assaad SI, Casty A, Ancukiewicz M, Yeh E, Molokhia P, Attia K, Sullivan T, Kuter I, Boucher Y, Powell SN. Paclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancers in patients treated with neoadjuvant chemotherapy: clinical implications [Abstract]. J Clin Oncol March 2005; 23 (9): 19511961.CrossRefGoogle Scholar